Company: TVRD
Filing Date: 2025-10-20
Form Type: S-1/A
Source: 0001104659-25-100896
Chunk: 327

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-20
Form: S-1/A
Chunk 327
---
--|
| Prepaid research and development expenses       | ​ | ​ | ​                  | $ | 18 | ​ | ​ | ​ | ​    | $ | 3,203 | ​ | ​ |
| Other prepaid expenses                          | ​ | ​ | ​                  | ​ | 54 | ​ | ​ | ​ | ​    | ​ |    36 | ​ | ​ |
| Total prepaid expenses and other current assets | ​ | ​ | ​                  | $ | 72 | ​ | ​ | ​ | ​    | $ | 3,239 | ​ | ​ |

5. Intangible Assets Intangible assets consisted of the following as of December 31, 2024 and 2023 (in thousands):

| ​                              
 ​                              | ​ 
 ​ | ​ 
 ​ | As of December 31, 
 2024               |   |      |   | ​ | ​ | 2023 |   |      |   | ​ 
 ​ |
|:-------------------------------|:--|:--|:-------------------|:--|-----:|:--|:--|:--|:-----|:--|-----:|:--|:--|
| Licensed patent rights         | ​ | ​ | ​                  | $ |  826 | ​ | ​ | ​ | ​    | $ |  826 | ​ | ​ |
| Less: accumulated amortization | ​ | ​ | ​                  | ​ | -441 | ​ | ​ | ​ | ​    | ​ | -378 | ​ | ​ |
| Total intangible assets, net   | ​ | ​ | ​                  | $ |  385 | ​ | ​ | ​ | ​    | $ |  448 | ​ | ​ |

As of December 31, 2024, the expected remaining amortization expense is as follows (in thousands):

| Year Ended December 31, 
 2025                    | ​ 
 ​ | ​ 
 ​ | Amount 
 ​      | ​ |  63 | ​ | ​ 
 ​ |
|:------------------------|:--|:--|:-------|:--|----:|:--|:--|
| 2026                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| 2027                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| 2028                    | ​ | ​ | ​      | ​ |  63